The intervention study is designed to evaluate nutrient bioavailability and physiological impact of two selected microalgae species of interest in a randomized study in humans. The controlled study in parallel design will be conducted with healthy males and females between 20 and 35 years.
The microalgae are selected depending on their contents of long-chain omega-3 fatty acids, e.g. eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), high-quality protein (focus: essential amino acids), dietary fibers but also vitamin D pre-cursors and further vitamins, minerals and trace elements.The nutrient bioavailability is evaluated in a controlled, randomized, double-blind study in parallel design. The intervention products (smoothie enriched with Chlorella pyrenoidosa, Nannochloropsis salina) are consumed daily over 14 days. In addition, the background diet is standardised by provision of defined menu plans ensuring an optimal energy and nutrient intake. The control group I receive no intervention products and no menu plans and control group II receive a smoothie without microalage and defined menu plans. A sup-group of five participants per group consume a test meal after the fasting blood sampling on the first study day. This is followed by a postprandial blood sampling after 30, 60, 90, 120 and 180 minutes. The NovAL study is conducted to evaluate the bioavailability of nutrients such as omega-3 LC-PUFA, vitamin D, vitamin B12, further vitamins, amino acids, minerals, and trace elements from the selected microalgae species. Therefore, the concentration of these valuable nutrients and relevant markers of their status in humans (e.g. vitamin B12 status: holo-transcobalamin, methylmalonic acid, homocysteine; iron status: ferritin, transferrin, transferrin saturation) are analysed in the human biofluids (serum/plasma, erythrocytes, 24 h urine) before and after defined consumption of the selected microalgae species over 14 days. Besides the comprehensive analysis of the nutrient status in humans, cardiovascular risk factors and risk factors for diabetes mellitus type II are analysed. Thus, the NovAL study allows the assessment of i) the nutrient bioavailability from the selected microalgae species but also ii) their contribution on nutrient supply and prevention of non-communicable diseases such as cardiovascular diseases or diabetes mellitus type.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
80
Smoothie with microalgae I: Chlorella pyrenoidosa, Smoothie with microalgae II: Nannochloropsis salina, Smoothie without microalgae
Friedrich Schiller University
Jena, Thuringia, Germany
EPA concentration in plasma lipids
concentration of eicosapentaenoic acid (EPA) in % fatty acid methyl esthers (FAME) in plasma lipids
Time frame: change from baseline after 2 weeks
blood lipids
total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides in mmol/l
Time frame: change from baseline after 2 weeks
anthropometric data
body water, body fat, lean body mass, extracellular mass (ECM), body cell mass (BCM) in %
Time frame: change from baseline after 2 weeks
body mass index
body mass index (kg/m2)
Time frame: change from baseline after 2 weeks
blood pressure
systolic blood pressure (mm Hg) diastolic blood pressure (mmHg)
Time frame: change from baseline after 2 weeks
inflammation marker (blood)
high-sensitive c-reactive protein (mg/dl)
Time frame: change from baseline after 2 weeks
homocysteine
homocysteine (µmol/l)
Time frame: change from baseline after 2 weeks
holotranscobalamine
holotranscobalamine (pmol/l)
Time frame: change from baseline after 2 weeks
glucose (fasting)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
glucose (fasting) (mmol/l)
Time frame: change from baseline after 2 weeks
insulin (fasting)
insulin (fasting) (mU/l)
Time frame: change from baseline after 2 weeks
hemoglobin A1c (fasting)
hemoglobin A1c (fasting) (%)
Time frame: change from baseline after 2 weeks
malodialdehyde modified LDL cholesterol
malodialdehyde modified LDL cholesterol (U/l)
Time frame: change from baseline after 2 weeks
fatty acid distribution in plasma lipids
fatty acid distribution in plasma lipids in % FAME
Time frame: change from baseline after 2 weeks
aspartate transaminase
aspartate transaminase (ASAT) in µmol/l\*s
Time frame: change from baseline after 2 weeks
alanine transaminase
alanine transaminase (ALAT) in µmol/l\*s
Time frame: change from baseline after 2 weeks
gamma-glutamyltransferase
gamma-glutamyltransferase (gGT) in µmol/l\*s
Time frame: change from baseline after 2 weeks
lactate dehydrogenase
lactate dehydrogenase (LDH) in µmol/l\*s
Time frame: change from baseline after 2 weeks
cholinesterase
cholinesterase in µmol/l\*s
Time frame: change from baseline after 2 weeks
kalium
kalium in mmol/l
Time frame: change from baseline after 2 weeks
calcium
calcium in mmol/l
Time frame: change from baseline after 2 weeks
transferrin
transferrin (g/l)
Time frame: change from baseline after 2 weeks
ferritin
ferritin (µg/l)
Time frame: change from baseline after 2 weeks
iron
iron (mg/dl)
Time frame: change from baseline after 2 weeks
vitamin A
vitamin A (mmol/l)
Time frame: change from baseline after 2 weeks
vitamin D
vitamin D (nmol/l)
Time frame: change from baseline after 2 weeks
vitamin E
vitamin E (µmol/l)
Time frame: change from baseline after 2 weeks
vitamin B1
vitamin B1 (nmol/l)
Time frame: change from baseline after 2 weeks
vitamin B6
vitamin B6 (nmol/l)
Time frame: change from baseline after 2 weeks
vitamin B12
vitamin B12 (pmol/l)
Time frame: change from baseline after 2 weeks
folic acid
folic acid (µg/l)
Time frame: change from baseline after 2 weeks
vitamin B2
vitamin B2 (µg/l)
Time frame: change from baseline after 2 weeks
vitamin C
vitamin C (mg/l)
Time frame: change from baseline after 2 weeks
vitamin H
vitamin H (ng/l)
Time frame: change from baseline after 2 weeks
iodine (24 h urine)
iodine (µmol/l)
Time frame: change from baseline after 2 weeks
selenium (24 h urine)
selenium (µmol/l)
Time frame: change from baseline after 2 weeks
copper (24 h urine)
copper (µmol/l)
Time frame: change from baseline after 2 weeks
zinc (24 h urine)
zinc (µmol/l)
Time frame: change from baseline after 2 weeks
manganese (24 h urine)
manganese (nmol/l)
Time frame: change from baseline after 2 weeks
natrium (24 h urine)
natrium (mmol/l)
Time frame: change from baseline after 2 weeks
magnesium (24 h urine)
magnesium (mmol/l)
Time frame: change from baseline after 2 weeks
creatinine (24 h urine)
creatinine (mmol/24 h)
Time frame: change from baseline after 2 weeks
albumine (24 h urine)
albumine (mg/l)
Time frame: change from baseline after 2 weeks
uric acid (24 h urine)
uric acid (mg/dl)
Time frame: change from baseline after 2 weeks